Literature DB >> 31815040

NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3.

Yiwei Li1, Lijuan Chen1, Lixing Feng1, Mengli Zhu1, Qiang Shen2, Yanfen Fang1,3, Xuan Liu2, Xiongwen Zhang1.   

Abstract

The mechanisms of how Never in Mitosis (NIMA) Related Kinase 2 (NEK2) coordinates altered signaling to malignant gastric cancer (GC) transformation remain unclear. Overexpression of NEK2 and KDM5B were observed in GC cell lines with high sensitivity to NEK2 inhibitors. Here we investigated the biological behaviors of NEK2 and the possible mechanisms of regulative effects of NEK2 on KDM5B in GC cell lines both in vitro and in vivo. The results showed that NEK2 and KDM5B were highly expressed in most of the 10 GC cell lines. NEK2 knockdown in MGC-803 cells led to suppression of cell proliferation and migration in vitro and tumor growth in vivo, while NEK2 overexpression in BGC-823 cells exhibited the reverse biological effect. When NEK2 was inhibited by NEK2 inhibitors or shNEK2, cellular KDM5B level decreased and H3K4me3 level increased, while overexpression of NEK2 resulted in enhanced KDM5B expression and decreased H3K4me3 level. Though direct interaction between NEK2 and KDM5B was excluded, NEK2 could regulate KDM5B/H3K4me3 expression through β-catenin/Myc both in vitro and in vivo, which was double confirmed by c-myc and KDM5B inhibitor experiments. Taken together, our study showed that NEK2 was highly expressed in GC cell lines and related to promoting cell proliferation, migration and tumor growth. A NEK2/β-catenin/Myc/KDM5B/H3K4me3 signaling pathway may contribute to the important carcinogenic role of NEK2-mediated malignant behaviors in GC. AJCR
Copyright © 2019.

Entities:  

Keywords:  Gastric cancer; KDM5B; NEK2; c-Myc; β-catenin

Year:  2019        PMID: 31815040      PMCID: PMC6895449     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  47 in total

1.  Nek8, a NIMA family kinase member, is overexpressed in primary human breast tumors.

Authors:  Alex J Bowers; John F Boylan
Journal:  Gene       Date:  2004-03-17       Impact factor: 3.688

Review 2.  Research update and opportunity of non-hormonal male contraception: Histone demethylase KDM5B-based targeting.

Authors:  Sarder Arifuzzaman; Md Saidur Rahman; Myung-Geol Pang
Journal:  Pharmacol Res       Date:  2018-12-11       Impact factor: 7.658

3.  Histone demethylase KDM5B collaborates with TFAP2C and Myc to repress the cell cycle inhibitor p21(cip) (CDKN1A).

Authors:  Ping-Pui Wong; Fabrizio Miranda; KaYi V Chan; Chiara Berlato; Helen C Hurst; Angelo G Scibetta
Journal:  Mol Cell Biol       Date:  2012-02-27       Impact factor: 4.272

Review 4.  β-catenin at the centrosome: discrete pools of β-catenin communicate during mitosis and may co-ordinate centrosome functions and cell cycle progression.

Authors:  Bertrade C Mbom; W James Nelson; Angela Barth
Journal:  Bioessays       Date:  2013-06-27       Impact factor: 4.345

Review 5.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

6.  Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities.

Authors:  Jian-Bei Xi; Yan-Fen Fang; Brendan Frett; Meng-Li Zhu; Tong Zhu; Yan-Nan Kong; Feng-Jie Guan; Yun Zhao; Xiong-Wen Zhang; Hong-Yu Li; Ming-Liang Ma; Wenhao Hu
Journal:  Eur J Med Chem       Date:  2016-12-12       Impact factor: 6.514

7.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

8.  The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer.

Authors:  Daniel G Hayward; Robert B Clarke; Alison J Faragher; Meenu R Pillai; Iain M Hagan; Andrew M Fry
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

9.  MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes.

Authors:  Shilpa S Dhar; Dongyu Zhao; Tao Lin; Bingnan Gu; Khusboo Pal; Sarah J Wu; Hunain Alam; Jie Lv; Kyuson Yun; Vidya Gopalakrishnan; Elsa R Flores; Paul A Northcott; Veena Rajaram; Wei Li; Ali Shilatifard; Roy V Sillitoe; Kaifu Chen; Min Gyu Lee
Journal:  Mol Cell       Date:  2018-05-31       Impact factor: 17.970

10.  KDM5B focuses H3K4 methylation near promoters and enhancers during embryonic stem cell self-renewal and differentiation.

Authors:  Benjamin L Kidder; Gangqing Hu; Keji Zhao
Journal:  Genome Biol       Date:  2014-02-04       Impact factor: 13.583

View more
  10 in total

1.  High expression of NEK2 promotes gastric cancer progression via activating AKT signaling.

Authors:  Hao Wan; Lin Xu; Huangbin Zhang; Feixiang Wu; Weiqiang Zeng; Taiyuan Li
Journal:  J Physiol Biochem       Date:  2020-11-17       Impact factor: 4.158

2.  Silencing of Nek2 suppresses the proliferation, migration and invasion and induces apoptosis of breast cancer cells by regulating ERK/MAPK signaling.

Authors:  Zeyu Xing; Menglu Zhang; Xin Wang; Jiaqi Liu; Gang Liu; Kexin Feng; Xiang Wang
Journal:  J Mol Histol       Date:  2021-05-19       Impact factor: 2.611

3.  Identification of Genes Universally Differentially Expressed in Gastric Cancer.

Authors:  Yidan Shi; Lishuang Qi; Haifeng Chen; Jiahui Zhang; Qingzhou Guan; Jun He; Meifeng Li; Zheng Guo; Haidan Yan; Ping Li
Journal:  Biomed Res Int       Date:  2021-01-21       Impact factor: 3.411

4.  The G-Protein-Coupled Estrogen Receptor (GPER) Regulates Trimethylation of Histone H3 at Lysine 4 and Represses Migration and Proliferation of Ovarian Cancer Cells In Vitro.

Authors:  Nan Han; Sabine Heublein; Udo Jeschke; Christina Kuhn; Anna Hester; Bastian Czogalla; Sven Mahner; Miriam Rottmann; Doris Mayr; Elisa Schmoeckel; Fabian Trillsch
Journal:  Cells       Date:  2021-03-11       Impact factor: 6.600

5.  Hypoxia Stimulates SUMOylation-Dependent Stabilization of KDM5B.

Authors:  Bingluo Zhou; Yiran Zhu; Wenxia Xu; Qiyin Zhou; Linghui Tan; Liyuan Zhu; Hui Chen; Lifeng Feng; Tianlun Hou; Xian Wang; Dingwei Chen; Hongchuan Jin
Journal:  Front Cell Dev Biol       Date:  2021-12-17

6.  NEK2 enhances malignancies of glioblastoma via NIK/NF-κB pathway.

Authors:  Jianyang Xiang; Wahafu Alafate; Wei Wu; Yichang Wang; Xiaodong Li; Wanfu Xie; Xiaobin Bai; Ruichun Li; Maode Wang; Jia Wang
Journal:  Cell Death Dis       Date:  2022-01-14       Impact factor: 9.685

7.  LncRNA SNHG1 promotes tumor progression and cisplatin resistance through epigenetically silencing miR-381 in breast cancer.

Authors:  Mingkun Zhang; Liu Yang; Lan Hou; Xueyuan Tang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  Preparation of an anti-NEK2 monoclonal antibody and its application in liver cancer.

Authors:  Qiuli Chen; Hui Li; Lichao Yang; Sha Wen; Xuejing Huang; Jiajuan Liu; Xiaoping Guo; Bing Hu; Gang Li; Min He
Journal:  BMC Biotechnol       Date:  2021-10-27       Impact factor: 2.563

9.  NEK2 plays an active role in Tumorigenesis and Tumor Microenvironment in Non-Small Cell Lung Cancer.

Authors:  Rui Bai; Cheng Yuan; Wenjie Sun; Jianguo Zhang; Yuan Luo; Yanping Gao; Yangyi Li; Yan Gong; Conghua Xie
Journal:  Int J Biol Sci       Date:  2021-05-11       Impact factor: 10.750

Review 10.  Nek2 Kinase Signaling in Malaria, Bone, Immune and Kidney Disorders to Metastatic Cancers and Drug Resistance: Progress on Nek2 Inhibitor Development.

Authors:  Dibyendu Dana; Tuhin Das; Athena Choi; Ashif I Bhuiyan; Tirtha K Das; Tanaji T Talele; Sanjai K Pathak
Journal:  Molecules       Date:  2022-01-06       Impact factor: 4.927

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.